查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1375851

人類免疫力缺乏病毒治療藥物市場規模、佔有率、趨勢分析報告：按藥物類型、藥物類別、地區和細分市場預測，2023-2030 年

Human Immunodeficiency Virus Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Drug Class (Entry & Fusion Inhibitors, Protease Inhibitors, Integrase Inhibitors), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 75 Pages | 商品交期: 2-10個工作天內

價格

人類免疫力缺乏病毒治療藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，2023年至2030年，全球人類免疫力缺乏病毒（HIV）-1治療藥物市場規模將以1.5%的年複合成長率成長，到2030年將達到113.4億美元。預計達到美元。

愛滋病毒仍然是全球最具挑戰性的公共衛生議題之一。

推動市場成長的關鍵因素包括愛滋病毒感染率上升，特別是在青少年中，由於無保護性行為、接觸被感染體液和組織污染的針頭和注射器，以及缺乏對感染危險因素的認知，據說這種情況正在增加。據英國的愛滋病毒/愛滋病慈善機構 AVERT 稱，2015 年估計有超過 3500 萬人罹患了愛滋病毒。

愛滋病毒對開發中國家和低度開發國家（主要是亞洲和非洲）的人們有重大影響。由於這種感染疾病目前無法治愈，抗逆轉錄病毒治療的首要目標是使用抗逆轉錄病毒病毒藥物治療患者的病毒，抗逆轉錄病毒藥物根據其作用機制分為六種不同的藥物類別，即抑制複製。

聯合治療使用至少兩到三種藥物類別的藥物，因為每一類藥物針對愛滋病毒生命週期的不同步驟。藥物組合的選擇是基於患者的病歷、抗逆轉錄病毒病毒藥物副作用的傾向以及與其他疾病的合併感染。

人類免疫力缺乏病毒治療藥物市場報告亮點

  • 整合酶抑制劑領域是成長最快的一類抗逆轉錄病毒藥物，吉利德科學公司和默克公司等主要公司預計將推出更多整合酶抑制劑。
  • 2022年，北美市場佔有率最大，超過51.5%。診斷設施的便利性是支持該地區市場擴張的關鍵因素之一。
  • 亞太地區是成長最快的地區，由於擁有發達的醫療基礎設施和適當的政府促進成長措施，預計在預測期內將保持其地位。
  • 就市場佔有率和藥物組合而言，吉利德科學公司 (Gilead Sciences) 是 HIV-1 治療領域的領導者，2015 年 ViiV Healthcare 緊隨其後。此外，預計其他較小的參與者將在未來幾年內透過管道藥物進入該領域。
  • 該產業的其他重要參與者包括艾伯維公司、百時美施貴寶公司和默克公司。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 人類免疫力缺乏病毒治療藥物市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 普及和成長前景圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 人類免疫力缺乏病毒療法：市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 人類免疫力缺乏病毒治療藥物市場：藥物類型估算及趨勢分析

  • 人類免疫力缺乏病毒治療市場：重點
  • 人類免疫力缺乏病毒治療市場：2022 年和 2030 年藥物類型趨勢和市場佔有率分析
  • 品牌藥品
  • 學名藥

第5章 人類免疫力缺乏病毒治療藥物市場：藥物類別估計和趨勢分析

  • 人類免疫力缺乏病毒治療市場：重點
  • 人類免疫力缺乏病毒治療市場：2022 年和 2030 年藥物類別趨勢和市場佔有率分析
  • 核苷類似物逆轉錄酶抑制劑 (NRTI)
  • 非核苷類逆轉錄酶抑制劑（NNRTI）
  • 進入抑制劑和融合抑制劑
  • 蛋白酶抑制劑 (PI)
  • 整合酶抑制劑
  • 共受體拮抗劑

第6章 人類免疫力缺乏病毒治療藥物市場：按地區估計和趨勢分析

  • 區域展望
  • 按地區分類的人類免疫力缺乏病毒治療市場：要點
  • 北美洲
    • 2018-2030 年北美市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 2018-2030 年歐洲市場估計與預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 2018-2030 年亞太市場估計與預測
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 2018-2030 年拉丁美洲市場估計與預測
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 2018 年至 2030 年 MEA 市場估計與預測
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • AbbVie Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Cipla Inc.
    • Genentech, Inc.
    • Gilead Sciences, Inc.
    • Merck & Co., Inc.
    • ViiV Healthcare
Product Code: GVR-1-68038-210-5

Human Immunodeficiency Virus Therapeutics Market Growth & Trends:

The global Human Immunodeficiency Virus (HIV)-1 therapeutics market size is expected to reach USD 11.34 billion by 2030, expanding at a CAGR of 1.5% from 2023 to 2030, according to a new report by Grand View Research, Inc.. HIV continues to be one of the most challenging public health issues worldwide.

The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.The estimated number of people suffering from HIV in 2015 was recorded to be more than 35 million according to AVERT, a UK-based HIV and AIDS charity.

HIV has vastly affected people from developing and under developed countries, mainly the Asian and African regions. As this infection is not curable at present, the primary aim of antiretroviral therapy is to suppress viral replication in patients usinganti-retroviral agents that are grouped into six different drug classes based on their mechanism of action.

The combination therapy entails medicines from at least two to three drug classes as each class targets different steps in the HIV lifecycle. The combination of drugs is chosen based on patients' medical history, predisposition to adverse effects of antiretroviral drugs, co-infections with other diseases, and others.

Human Immunodeficiency Virus Therapeutics Market Report Highlights:

  • Integrase inhibitors segment is expected to be the fastest growing class of antiretroviral drugs owing to the expected launch of additional integrase inhibitors by major players such as Gilead Sciences, In. and Merck & Co., Inc.
  • North America held the largest market share in 2022 with a share of over 51.5%. Easier access to diagnostic facilities is one of the key factors supporting sector expansion in this region.
  • Asia Pacific is projected to be the fastest growing regional segment and will retain its position over the forecast period owing to the enhancing healthcare infrastructure and presence of suitable government initiatives favoring growth
  • Gilead Sciences, Inc. was the leader in HIV-1 therapeutics sector with respect to market share and drug portfolio, followed byViiV Healthcare in 2015. In addition, in the coming years other small players are expected to enter this sector with their pipeline drugs.
  • Other important players in this industry include AbbVie, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., and Boehringer Ingelheim GmbH.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug type
    • 1.1.2. Drug class
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug type outlook
    • 2.2.2. Drug class outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Human Immunodeficiency Virus Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Human Immunodeficiency Virus Therapeutics: Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Human Immunodeficiency Virus Therapeutics Market: Drug Type Estimates & Trend Analysis

  • 4.1. Human Immunodeficiency Virus Therapeutics Market: Key Takeaways
  • 4.2. Human Immunodeficiency Virus Therapeutics Market: Drug Type Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Branded Drugs
    • 4.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Generic Drugs
    • 4.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Human Immunodeficiency Virus Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 5.1. Human Immunodeficiency Virus Therapeutics Market: Key Takeaways
  • 5.2. Human Immunodeficiency Virus Therapeutics Market: Drug Class Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    • 5.3.1. Nucleoside-analog reverse transcriptase inhibitors (NRTIs) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 5.4.1. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Entry and Fusion Inhibitors
    • 5.5.1. Entry and fusion inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Protease Inhibitors (PIs)
    • 5.6.1. Protease inhibitors (PIs) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Integrase Inhibitors
    • 5.7.1. Integrase inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.8. Coreceptor Antagonists
    • 5.8.1. Coreceptor antagonists market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Human Immunodeficiency Virus Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Human Immunodeficiency Virus Therapeutics Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. North America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. U.S. market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Canada market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. Europe market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. UK
      • 6.4.2.1. UK market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. Germany
      • 6.4.3.1. Germany market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. France
      • 6.4.4.1. France market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Italy market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Spain market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Sweden market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Norway market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.9. Denmark
      • 6.4.9.1. Denmark market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Japan market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. China
      • 6.5.3.1. China market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. India
      • 6.5.4.1. India market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
    • 6.5.5. Australia
      • 6.5.5.1. Australia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Thailand market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.7. South Korea
      • 6.5.7.1. South Korea market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Latin America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Brazil market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Mexico
      • 6.6.3.1. Mexico market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.4. Argentina
      • 6.6.4.1. Argentina market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. MEA market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million) (Revenue, USD Million)
    • 6.7.3. South Africa
      • 6.7.3.1. South Africa market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. UAE market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Kuwait market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. AbbVie Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Boehringer Ingelheim International GmbH
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Bristol-Myers Squibb Company
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Cipla Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Genentech, Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Gilead Sciences, Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Merck & Co., Inc.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. ViiV Healthcare
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 3 North America human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 North America human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 6 U.S. human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 Canada human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 8 Canada human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 Europe human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 10 Europe human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 11 Europe human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 13 Germany human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 UK human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 15 UK human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 16 France human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 17 France human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Italy human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 19 Italy human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 Spain human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 21 Spain human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Sweden human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 23 Sweden human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 24 Norway human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 25 Norway human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 Denmark human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 27 Denmark human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 31 China human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 32 China human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 Japan human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 34 Japan human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 India human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 36 India human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 37 Australia human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 38 Australia human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 39 Thailand human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 40 Thailand human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 41 South Korea human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 42 South Korea human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 43 Latin America human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 44 Latin America human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 45 Latin America human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 47 Brazil human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 48 Mexico human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 49 Mexico human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 50 Argentina human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 51 Argentina human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa human immunodeficiency virus therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 56 South Africa human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 59 UAE human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 60 UAE human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 61 Kuwait human immunodeficiency virus therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait human immunodeficiency virus therapeutics market, by drug class, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Human immunodeficiency virus therapeutics: Market outlook
  • Fig. 9 Human immunodeficiency virus therapeutics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Human immunodeficiency virus therapeutics market driver impact
  • Fig. 15 Human immunodeficiency virus therapeutics market restraint impact
  • Fig. 16 Human immunodeficiency virus therapeutics market strategic initiatives analysis
  • Fig. 17 Human immunodeficiency virus therapeutics market: Drug type movement analysis
  • Fig. 18 Human immunodeficiency virus therapeutics market: Drug type outlook and key takeaways
  • Fig. 19 Branded drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Generic drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Human immunodeficiency virus therapeutics market: Drug class movement analysis
  • Fig. 22 Human immunodeficiency virus therapeutics market: Drug class outlook and key takeaways
  • Fig. 23 Nucleoside-analog reverse transcriptase inhibitors (NRTIs) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Entry and fusion inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Protease inhibitors (PIs) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Integrase inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Coreceptor antagonists market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Global human immunodeficiency virus therapeutics market: Regional movement analysis
  • Fig. 30 Global human immunodeficiency virus therapeutics market: regional outlook and key takeaways
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)